Experimental Alzheimer's drug may slow cognitive decline
The experimental intravenous drug donanemab may slow cognitive decline in people living with Alzheimer's, according to a Phase 2 clinical trial. Researchers found that the drug slowed the decline of cognition and daily function in participants by 32 percent after 76 weeks compared to those who received a placebo. The research is early, but Maria Carrillo, Alzheimer’s Association chief science officer, says the drug “could be a first step toward slowing more significantly, or stopping, cognitive decline in these earlier stages."
